A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma
Phase of Trial: Phase II
Latest Information Update: 09 Aug 2017
At a glance
- Drugs Pilaralisib (Primary)
- Indications Endometrial cancer
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Sanofi
- 08 Jan 2013 Status changed from recruiting to discontinued, according to a Sanofi media release.
- 20 Jun 2012 Planned End Date changed from 1 Mar 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.
- 06 Jun 2012 Official Title amended as reported by ClinicalTrials.gov.